Skip to main content

Borderline Personality Disorder

9
Pipeline Programs
15
Companies
18
Clinical Trials
3 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
1
2
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
4100%
+ 16 programs with unclassified modality

On Market (1)

Approved therapies currently available

Otsuka
REXULTIApproved
brexpiprazole
Otsuka
Atypical Antipsychotic [EPC]oral2015
630M Part D

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Otsuka
OtsukaJapan - Tokushima
3 programs
2
1
1
BrexpiprazolePhase 2/3Small Molecule1 trial
BrexpiprazolePhase 2Small Molecule1 trial
RexultiPhase 21 trial
Active Trials
NCT04100096Completed332Est. Jun 2021
NCT03418675Completed80Est. Apr 2021
NCT04186403Completed201Est. Sep 2021
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
LamotriginePhase 4
Prevail Therapeutics
3 programs
2
OlanzapinePhase 31 trial
OlanzapinePhase 31 trial
olanzapineN/A1 trial
Active Trials
NCT00275301Completed19Est. Dec 2008
NCT00091650Completed300Est. Nov 2005
NCT00088036Completed450Est. Jan 2006
Intra-Cellular Therapies
1 program
1
CaplytaPhase 21 trial
Active Trials
NCT05356013Completed60Est. Dec 2025
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
1
EscitalopramPhase 21 trial
Active Trials
NCT01103180Terminated70Est. Nov 2014
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
2 programs
Transcranial Magnetic StimulationN/A1 trial
Transcranial Magnetic StimulationN/A1 trial
Active Trials
NCT07197502Recruiting30Est. Dec 2027
NCT07223619Active Not Recruiting20Est. Dec 2027
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
BI 3031185PHASE_11 trial
BI 1358894PHASE_21 trial
Active Trials
NCT07001475Recruiting96Est. Nov 2026
NCT04566601Completed390Est. Jan 2023
Young BioPharma
Young BioPharmaMA - Lowell
1 program
Amygdala NeurofeedbackN/A1 trial
Active Trials
NCT05398627Active Not Recruiting100Est. Apr 2026
Abbott
AbbottABBOTT PARK, IL
1 program
Depakote ERN/A1 trial
Active Trials
NCT00222482Completed15Est. Sep 2005
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Dialectical Behavior Therapy SkillsN/A1 trial
Active Trials
NCT03060902Completed93Est. May 2022
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Mentalization-Based TreatmentN/A1 trial
Active Trials
NCT06018272Recruiting304Est. Mar 2028
Innovation Pharmaceuticals
1 program
Paper diary sheetN/A1 trial
Active Trials
NCT03191565Unknown78Est. Apr 2020
Genomics
GenomicsUK - Oxford
1 program
vafidemstatPHASE_2Small Molecule1 trial
Active Trials
NCT04932291Completed210Est. Nov 2023
Oryzon Genomics
Oryzon GenomicsMA - Cambridge
1 program
vafidemstatPHASE_2Small Molecule

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Prevail TherapeuticsOlanzapine
Prevail TherapeuticsOlanzapine
OtsukaBrexpiprazole
Intra-Cellular TherapiesCaplyta
Genomicsvafidemstat
Boehringer IngelheimBI 1358894
OtsukaBrexpiprazole
OtsukaRexulti
Temple TherapeuticsEscitalopram
Boehringer IngelheimBI 3031185
Angeles TherapeuticsTranscranial Magnetic Stimulation
Heidelberg PharmaMentalization-Based Treatment
Angeles TherapeuticsTranscranial Magnetic Stimulation
Young BioPharmaAmygdala Neurofeedback
Oregon TherapeuticsDialectical Behavior Therapy Skills

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 2,848 patients across 18 trials

NCT00091650Prevail TherapeuticsOlanzapine

Olanzapine in Patients With Borderline Personality Disorder

Start: Mar 2004Est. completion: Nov 2005300 patients
Phase 3Completed
NCT00088036Prevail TherapeuticsOlanzapine

Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder

Start: Feb 2004Est. completion: Jan 2006450 patients
Phase 3Completed
NCT04186403OtsukaBrexpiprazole

Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)

Start: Jan 2020Est. completion: Sep 2021201 patients
Phase 2/3Completed
NCT05356013Intra-Cellular TherapiesCaplyta

Caplyta in Borderline Personality Disorder

Start: May 2023Est. completion: Dec 202560 patients
Phase 2Completed
NCT04932291Genomicsvafidemstat

Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population

Start: Mar 2021Est. completion: Nov 2023210 patients
Phase 2Completed
NCT04566601Boehringer IngelheimBI 1358894

A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder

Start: Nov 2020Est. completion: Jan 2023390 patients
Phase 2Completed
NCT04100096OtsukaBrexpiprazole

A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

Start: Oct 2019Est. completion: Jun 2021332 patients
Phase 2Completed
NCT03418675OtsukaRexulti

Brexpiprazole in Borderline Personality Disorder

Start: Nov 2018Est. completion: Apr 202180 patients
Phase 2Completed
NCT01103180Temple TherapeuticsEscitalopram

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

Start: Sep 2010Est. completion: Nov 201470 patients
Phase 2Terminated
NCT07001475Boehringer IngelheimBI 3031185

A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

Start: Aug 2025Est. completion: Nov 202696 patients
Phase 1Recruiting
NCT07197502Angeles TherapeuticsTranscranial Magnetic Stimulation

Treatment of Borderline Personality Disorder With rTMS

Start: Mar 2025Est. completion: Dec 202730 patients
N/ARecruiting
NCT06018272Heidelberg PharmaMentalization-Based Treatment

Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany

Start: Feb 2024Est. completion: Mar 2028304 patients
N/ARecruiting
NCT07223619Angeles TherapeuticsTranscranial Magnetic Stimulation

PILOT Phase: BPD Study

Start: Jan 2024Est. completion: Dec 202720 patients
N/AActive Not Recruiting
NCT05398627Young BioPharmaAmygdala Neurofeedback

Neurofeedback for Borderline Personality Disorder

Start: Sep 2022Est. completion: Apr 2026100 patients
N/AActive Not Recruiting
NCT03060902Oregon TherapeuticsDialectical Behavior Therapy Skills

Preschooler Emotion Regulation in the Context of Maternal Borderline Personality Disorder

Start: Oct 2017Est. completion: May 202293 patients
N/ACompleted
NCT03191565Innovation PharmaceuticalsPaper diary sheet

Using Smartphones for Selfmonitoring of Skill-use i Dialectical Behavior Therapy

Start: Jun 2017Est. completion: Apr 202078 patients
N/AUnknown
NCT00275301Prevail Therapeuticsolanzapine

PET Imaging and Olanzapine Treatment in Borderline Personality Disorder

Start: Dec 2005Est. completion: Dec 200819 patients
N/ACompleted
NCT00222482AbbottDepakote ER

Depakote ER in Borderline Personality Disorder

Start: Mar 2003Est. completion: Sep 200515 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 2,848 patients
15 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.